Hunan Er-Kang Pharmaceutical Co Ltd
Company Profile
Business description
Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.
Contact
Kangping Road 167
National Economic and Technological Development Zone
Liuyang Changsha
Hunan410331
CHNT: +86 73184659108
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,497
Stocks News & Analysis
video
What does the RBA rate cut mean for investors?
stocks
Insights from reporting season: So far, so good
stocks
3 cheap ASX stocks owned by top rated funds
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,570.90 | 30.80 | -0.36% |
CAC 40 | 8,154.51 | 31.93 | 0.39% |
DAX 40 | 22,287.56 | 27.09 | -0.12% |
Dow JONES (US) | 43,428.02 | 748.63 | -1.69% |
FTSE 100 | 8,659.37 | 3.60 | -0.04% |
HKSE | 23,477.92 | 900.94 | 3.99% |
NASDAQ | 19,524.01 | 438.36 | -2.20% |
Nikkei 225 | 38,776.94 | 98.90 | 0.26% |
NZX 50 Index | 12,752.58 | 127.78 | -0.99% |
S&P 500 | 6,013.13 | 104.39 | -1.71% |
S&P/ASX 200 | 8,296.20 | 26.60 | -0.32% |
SSE Composite Index | 3,379.11 | 28.33 | 0.85% |